Evaluation of Aldosterone Suppression by Cinnarizine, a Putative Cav1.3 Inhibitor
A Cav1.3 ligand, cinnarizine, reduced aldosterone secretion from adrenocortical cells, but at maximum-soluble concentrations was less effective than the nonselective calcium blocker, nifedipine. At clinical doses, cinnarizine did not reduce plasma ARR in patients with PA, and, as in vitro, was inferior to nifedipine. The limited efficacy of high-dose nifedipine may be due to incomplete Cav1.3 blockade, or to a role for non-L-type calcium channels in aldosterone secretion.
Authors
- Angela E. Taylor (ORCID: https://orcid.org/0000-0002-5835-5643)
- Fozia Shaheen (ORCID: https://orcid.org/0000-0002-8123-4209)
- Elisabeth Ng (ORCID: https://orcid.org/0000-0001-6649-032X)
- Yun-Ni Lee
- Elena A B Aisha Azizan (ORCID: https://orcid.org/0000-0002-5549-4242)
- Morris J. Brown (ORCID: https://orcid.org/0000-0001-8409-1082)
- William M Drake (ORCID: https://orcid.org/0000-0002-7026-4250)
Institutions
- St Bartholomew's Hospital (GB)
- Queen Mary University of London (GB)
- University Kebangsaan Malaysia Medical Centre (MY)
- National Institutes of Biotechnology Malaysia (MY)
- William Harvey Research Institute (GB)
- University of Birmingham (GB)
- National University of Malaysia (MY)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1210/clinem/dgaf081
- Citations
- 1
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Queen Mary University of London
- National Institute for Health and Care Research
- Endocrine Society of Australia
- Medical Research Council
- National Health and Medical Research Council